Investigating the genetic factors in leiomyosarcoma development
PROJECT 2: Understanding the role of TP53 in LMS development
This study is looking at the genes that might cause leiomyosarcoma, a rare cancer, especially in people with certain hereditary cancer conditions, and it involves gathering genetic samples and family histories from patients to help improve testing and understand cancer risks better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10911940 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic basis of leiomyosarcoma (LMS), a rare type of cancer. It aims to identify genetic mutations, particularly in the TP53 gene, that may contribute to the development of LMS, especially in patients with hereditary cancer syndromes like Li-Fraumeni Syndrome. By analyzing a large group of LMS patients and their families, the study seeks to uncover patterns of cancer risk and improve genetic testing protocols. Patients may be asked to provide genetic samples and family history to help researchers gather comprehensive data.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with leiomyosarcoma, particularly those with a family history of hereditary cancer syndromes.
Not a fit: Patients with leiomyosarcoma who do not have a family history of cancer or those with non-hereditary forms of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better genetic testing and risk assessment for patients with leiomyosarcoma, potentially improving early detection and treatment options.
How similar studies have performed: Previous research has shown success in identifying genetic mutations associated with other hereditary cancer syndromes, suggesting a promising approach for this study.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Thomas, David — University of Michigan at Ann Arbor
- Study coordinator: Thomas, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.